Back to Newsroom

Luminex Corporation Receives FDA and European Clearance for a New Personalized Medicine Genotyping Assay, xTAG® CYP2C19 Kit

AUSTIN, Texas, Sept. 23, 2013 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced it has received U.S. FDA and European clearance for a comprehensive genotyping assay, xTAG® CYP2C19 Kit.  This new test enables a personalized approach to aid physicians in determining patient treatment plans based on certain genetic variants of the P450 2C19 gene.